Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19066166rdf:typepubmed:Citationlld:pubmed
pubmed-article:19066166lifeskim:mentionsumls-concept:C0813971lld:lifeskim
pubmed-article:19066166lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:19066166lifeskim:mentionsumls-concept:C0812380lld:lifeskim
pubmed-article:19066166lifeskim:mentionsumls-concept:C1705691lld:lifeskim
pubmed-article:19066166lifeskim:mentionsumls-concept:C0178648lld:lifeskim
pubmed-article:19066166lifeskim:mentionsumls-concept:C0019409lld:lifeskim
pubmed-article:19066166lifeskim:mentionsumls-concept:C1533148lld:lifeskim
pubmed-article:19066166lifeskim:mentionsumls-concept:C1512498lld:lifeskim
pubmed-article:19066166pubmed:issue4lld:pubmed
pubmed-article:19066166pubmed:dateCreated2009-3-30lld:pubmed
pubmed-article:19066166pubmed:abstractTextFusion of the hormone-regulated gene TMPRSS2 with ERG occurs in 50-70% of prostate cancers; fusions of ETV1 with one of several partners occur in approximately 10% of prostate cancers. These two translocations are mutually exclusive. The presence of subclasses of these chromosomal rearrangements may indicate worse prognosis, with the subclass 2+Edel, which has duplication of TMPRSS2:ERG fusion sequences, indicating particularly poor survival. However as this case shows, significant heterogeneity can exist with ERG and ETV1 rearrangements occurring in both prostate intra-epithelial neoplasia and cancer in the same prostatectomy specimen and with adjacent cancer areas containing a single copy, duplication and even triplication of the rearranged locus. As the majority of ETS gene fusions are hormone regulated, they could explain the pathogenesis underlying exquisitely hormone-sensitive prostate cancer. This is exemplified by the case presented here of a patient diagnosed in 1991 who remains asymptomatic and chemotherapy-naïve after having long-lasting tumour responses to multiple lines of systemic hormonal treatments.lld:pubmed
pubmed-article:19066166pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19066166pubmed:languageenglld:pubmed
pubmed-article:19066166pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19066166pubmed:citationSubsetAIMlld:pubmed
pubmed-article:19066166pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19066166pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19066166pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19066166pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19066166pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19066166pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19066166pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19066166pubmed:statusMEDLINElld:pubmed
pubmed-article:19066166pubmed:monthAprlld:pubmed
pubmed-article:19066166pubmed:issn1472-4146lld:pubmed
pubmed-article:19066166pubmed:authorpubmed-author:ParkesLLlld:pubmed
pubmed-article:19066166pubmed:authorpubmed-author:CooperC SCSlld:pubmed
pubmed-article:19066166pubmed:authorpubmed-author:JamesonCClld:pubmed
pubmed-article:19066166pubmed:authorpubmed-author:MoreiraJJlld:pubmed
pubmed-article:19066166pubmed:authorpubmed-author:DearnaleyDDlld:pubmed
pubmed-article:19066166pubmed:authorpubmed-author:AttardGGlld:pubmed
pubmed-article:19066166pubmed:authorpubmed-author:FlohrPPlld:pubmed
pubmed-article:19066166pubmed:authorpubmed-author:de BonoJ SJSlld:pubmed
pubmed-article:19066166pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19066166pubmed:volume62lld:pubmed
pubmed-article:19066166pubmed:ownerNLMlld:pubmed
pubmed-article:19066166pubmed:authorsCompleteYlld:pubmed
pubmed-article:19066166pubmed:pagination373-6lld:pubmed
pubmed-article:19066166pubmed:meshHeadingpubmed-meshheading:19066166...lld:pubmed
pubmed-article:19066166pubmed:meshHeadingpubmed-meshheading:19066166...lld:pubmed
pubmed-article:19066166pubmed:meshHeadingpubmed-meshheading:19066166...lld:pubmed
pubmed-article:19066166pubmed:meshHeadingpubmed-meshheading:19066166...lld:pubmed
pubmed-article:19066166pubmed:meshHeadingpubmed-meshheading:19066166...lld:pubmed
pubmed-article:19066166pubmed:meshHeadingpubmed-meshheading:19066166...lld:pubmed
pubmed-article:19066166pubmed:meshHeadingpubmed-meshheading:19066166...lld:pubmed
pubmed-article:19066166pubmed:meshHeadingpubmed-meshheading:19066166...lld:pubmed
pubmed-article:19066166pubmed:meshHeadingpubmed-meshheading:19066166...lld:pubmed
pubmed-article:19066166pubmed:meshHeadingpubmed-meshheading:19066166...lld:pubmed
pubmed-article:19066166pubmed:meshHeadingpubmed-meshheading:19066166...lld:pubmed
pubmed-article:19066166pubmed:year2009lld:pubmed
pubmed-article:19066166pubmed:articleTitleHormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity.lld:pubmed
pubmed-article:19066166pubmed:affiliationThe Royal Marsden NHS Foundation Trust, Sutton, UK.lld:pubmed
pubmed-article:19066166pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19066166pubmed:publicationTypeCase Reportslld:pubmed
pubmed-article:19066166pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed